Funding Summary
Total Funding
$1B+
Latest Valuation
~$600M (public market cap)
About
Flagship Pioneering-backed company developing both ex vivo and in vivo cell engineering approaches. Hypoimmune technology creates universal donor cells, and fusogen platform delivers genetic cargo without viral vectors.
Products
hypoimmune-cell-therapyin-vivo-cell-engineeringfusogen-delivery
Recent Developments
Recent developments are auto-populated from tagged articles in the Newsfeed. Browse all news →